| Literature DB >> 25434931 |
Matthew L Stoll, Ranjit Kumar, Casey D Morrow, Elliot J Lefkowitz, Xiangqin Cui, Anna Genin, Randy Q Cron, Charles O Elson.
Abstract
INTRODUCTION: Prior studies have established altered microbiota and immunologic reactivity to enteric commensal organisms in inflammatory bowel disease (IBD). Since intestinal inflammation is present in a subset of patients with both pediatric and adult spondyloarthritis (SpA), we hypothesized that SpA patients may also have altered microbiota and immune responsiveness to enteric organisms.Entities:
Mesh:
Year: 2014 PMID: 25434931 PMCID: PMC4272554 DOI: 10.1186/s13075-014-0486-0
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Patient population
|
|
|
|
|---|---|---|
| Number | 25 | 13 |
| Age, years, median, range | 13.0, 7.0 to 19.0 | 13.0, 5.8 to 18.0 |
| Male:female, number | 11:14 | 6:7 |
| Body mass index, median, range | 20, 16 to 41 | 23.7, 14.0 to 43.0 |
| Disease duration, years, median, range | 2.4, 0 to 8.2 | N/A |
| HLA-B27+, number | 9/24 (38%) | 0/3 |
| Known inflammatory bowel disease, number | 2 (8.0%) | 0 |
| Erythrocyte sedimentation rate, median, range | 9, 3 to 56 | |
| Medications | ||
| None, number | 7 (28%) | 13 (100%) |
| Methotrexate alone, number | 2 (8.0%) | |
| Pentasa alone, number | 1 (4.0%) | |
| Anti-TNF +/− conventional DMARD | 15 (60%) |
DMARD, disease-modifying anti-rheumatic drug (methotrexate, leflunomide); TNF, tumor necrosis factor; N/A, not applicable.
Figure 1Decreased abundance of genus in enthesitis-related arthritis (ERA) patients compared to controls. (A) The relative abundance of the top 20 taxa are shown. Although the taxa were evaluated at the genus level, some of the operational taxonomic units (OTUs) were only identified at the family level or above. Negative values (left) indicate higher frequency in controls, and positive values (right) indicate higher frequencies in patients. Statistically significant differences (Mann-Whitney U-test) are depicted in a darker gray color. (B) The distribution of F. prausnitzii levels is shown.
Figure 2Spondyloarthritis (SpA) patients have two distinct clusters. In principal coordinates analysis (A) each subject is a separate dot; the closer two subjects are in space, the more similar their sequence data. Enthesitis-related arthritis (ERA) subjects are shown in blue, controls in red. The asterisks over eight of the subjects indicate subjects identified as well with the pvclust bootstrap analysis (B). The same eight subjects are present in the identified cluster.
Figure 3Alpha diversity metric comparing clusters 1 and 2. The Shannon index is shown in A; this measures species evenness, or the probability of being able to predict the identity of a randomly drawn sequence. The phylogenetic diversity is shown in B; this evaluates the length of all branches of the phylogenetic tree of a given population [22].
Comparison of clinical and laboratory features of children in cluster 1 versus cluster 2
|
|
|
|
|
|---|---|---|---|
| Number | 8 | 17 | N/A |
| Age, years, median, range | 13, 7 to 18 | 13, 7.5 to 19 | 0.932 |
| Male:female, number | 1:7 | 13:4 | 0.007 |
| Body mass index, median, range | 20, 16 to 33 | 23, 16 to 41 | 0.374 |
| Disease duration, years, median, range | 1.6, 0 to 6.5 | 3, 0 to 8.2 | 0.238 |
| HLA-B27+, number | 3/8, 38% | 6/16, 38% | 1.000 |
| Known inflammatory bowel disease, number | 1, 12% | 1, 5.9% | 1.000 |
| Erythrocyte sedimentation rate, number: median, range | 7: 10, 6 to 50 | 13: 9, 3 to 56 | 0.536 |
| Medications, number | |||
| None | 2, 25% | 5, 29% | |
| Methotrexate alone | 0 | 2, 12% | |
| Pentasa alone | 0 | 1, 5.9% | |
| Anti-TNF +/− conventional DMARD | 6, 75% | 9, 53% |
DMARD, disease-modifying anti-rheumatic drug; TNF, tumor necrosis factor; N/A, not applicable.
Median antibody levels (o.d.) against several of the bacteria differentially present between patients and controls
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| 0.11, | 0.16, | 0.094 | 0.41, | 0.43, | 0.536 |
| 0 to 0.21 | 0.094 to 0.343 | 0.095 to 1.3 | 0.20 to 1.6 | |||
|
| 0.15, | 0.18, | 0.112 | 0.45, | 0.46, | 0.742 |
| 0.043 to 0.51 | 0.14 to 0.29 | 0.21 to 1.6 | 0.22 to 1.6 | |||
ERA, enthesitis-related arthritis. Values are median (min - max). o.d. = optical density.
Figure 4Divergent relationships between IgA levels and fecal content, between patients and controls. Enthesitis-related arthritis (ERA) subjects are depicted in blue (broken line); controls are red (solid line).
Figure 5Divergent relationships between IgA levels and fecal content, between patients and controls. Enthesitis-related arthritis (ERA) subjects are depicted in blue (broken line); controls are red (solid line).